Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Getafe – page 28

3 191 clinical trials in Getafe, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Getafe at a glance
3 191
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 191 trials in Getafe

Open in trial search

Homocystinuria

Recruiting

A study to evaluate the safety and effectiveness of pegtibatinase in patients aged 12 to 65 years with classical homocystinuria.

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegtibatinase
  • Sponsor:Travere Therapeutics Inc.

Neoplasm malignant

Recruiting

A study of PM54 and pembrolizumab in adults with advanced cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pharma Mar S.A.

Hypercholesterolaemia

Recruiting

Study of K-924 (ezetimibe and pitavastatin) in patients with high cholesterol who have an inadequate response to pitavastatin

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ezetimibe
  • Sponsor:Kowa Co. Ltd.

Hepatocellular carcinoma

Recruiting

A study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Thrombocytopenia

Recruiting

A study to evaluate the effectiveness and safety of efaglomograstim alfa in patients with low blood platelet counts caused by chemotherapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rafutrombopag ethanolamine
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Systemic scleroderma+1

Recruiting

A study to evaluate the safety and effectiveness of QEL-005 in patients with diffuse cutaneous systemic sclerosis and difficult to treat rheumatoid arthritis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:QEL-005
  • Sponsor:Quell Therapeutics Limited

Obesity+1

Recruiting

A study of eloralintide in adults with persistent obesity or overweight who are currently treated with a weekly incretin medication

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Clear cell renal cell carcinoma+1

Recruiting

A study of PF-08634404, ipilimumab, and axitinib in adults with advanced or metastatic kidney cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Pfizer Inc.

Progressive supranuclear palsy

Recruiting

A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:NIO752
  • Sponsor:Novartis Pharma AG

Neoplasm malignant

Recruiting

A study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

B-cell small lymphocytic lymphoma

Recruiting

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:BeOne Medicines I GmbH

Colon cancer

Recruiting

A study to evaluate the safety and effectiveness of darizmetinib hydrochloride in patients who have had liver surgery due to colon cancer metastases

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Darizmetinib hydrochloride
  • Sponsor:HepaRegeniX GmbH

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Getafe

What the registry says about research in the country

01 Respiratory & Infectious Diseases

Groundbreaking research focusing on pneumococcal disease prevention and treatment of acute respiratory distress syndrome, including innovative vaccine development and therapeutic approaches.

  • Pneumococcal Vaccines
  • ARDS Treatment
  • Community-Acquired Pneumonia

Studies aim to enhance protection against respiratory infections and improve patient outcomes in severe cases.

02 Neurological Disorders

Innovative clinical trials exploring treatments for multiple sclerosis and Menière's disease, focusing on disease modification and symptom management.

  • MS Treatment Comparisons
  • Inner Ear Disorders
  • Neurological Therapeutics

Research aims to improve quality of life and disease management for patients with chronic neurological conditions.

03 Cardiovascular & Renal Studies

Comprehensive research into chronic renal disease, pulmonary embolism, and vascular conditions, evaluating new therapeutic approaches.

  • Renal Disease Management
  • Pulmonary Embolism Treatment
  • Vascular Health

Studies focus on improving outcomes in patients with complex cardiovascular and kidney conditions.

04 Oncology & Specialized Care

Advanced research in prostate cancer treatment and management of vitiligo, exploring innovative therapeutic options.

  • Cancer Treatment
  • Dermatological Conditions
  • Specialized Therapies

Trials aim to develop more effective treatments for both oncological and dermatological conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.